title: The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children.
authors.forename: T T
authors.initials: TT
authors.lastname: Biss
authors.forename: P J
authors.initials: PJ
authors.lastname: Avery
authors.forename: M D
authors.initials: MD
authors.lastname: Williams
authors.forename: L R
authors.initials: LR
authors.lastname: Brandão
authors.forename: J D
authors.initials: JD
authors.lastname: Grainger
authors.forename: F
authors.initials: F
authors.lastname: Kamali
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000378:metabolism; D001711:Biotransformation; D001777:Blood Coagulation / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D065729:Cytochrome P-450 CYP2C9; D016903:Drug Monitoring / Q000379:methods; D004739:England; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006470:Hemorrhage / Q000139:chemically induced / Q000235:genetics; D006801:Humans; D007223:Infant; D019934:International Normalized Ratio; D008297:Male; D006899:Mixed Function Oxygenases / Q000235:genetics* / Q000378:metabolism; D009864:Ontario; D010597:Pharmacogenetics; D010641:Phenotype; D012189:Retrospective Studies; D012307:Risk Factors; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D000925:Anticoagulants; D014859:Warfarin; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases